Delongchamps N B, Conquy S, Defontaines J, Zerbib M, Peyromaure M
Service d'urologie, université Paris Descartes, hôpital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
Prog Urol. 2012 Sep;22(10):590-7. doi: 10.1016/j.purol.2012.05.001. Epub 2012 Jun 14.
To evaluate the feasibility, tolerance and short-term efficacy of intra-prostatic UroLift(®) implants in four patients with symptomatic benign prostatic hyperplasia.
Four patients with symptomatic BPH, already treated with alpha-blockers, were consecutively treated with intra-prostatic UroLift(®) implants under general anaesthesia. A bladder catheter was placed postoperatively. Alpha-blocker therapy was withdrawn 7 days postoperatively. The clinical and morphological characteristics of the patients were noted. Low urinary tract (IPSS) and sexual symptoms (IIEF5, MSHQ-EjD), maximum urinary flow rate and post voiding residual volume were evaluated preoperatively and at 1 month.
Median age was of 69 [52-74] years old and median prostatic volume of 50 cm(3) [40-80]. Median procedure time was of 11 minutes [6-15]. Intra- and postoperative outcomes were uneventful. At 1 month, the mean IPSS and IPSS-QOL improvement were of 46 % and 58 %, respectively. One patient reported no improvement in his urinary and sexual symptoms. In the other three patients, the maximum urinary flow rate was improved, the post voiding residual improved in two patients and similar in one. No alteration in erection or ejaculation functions was reported.
In our initial experience, intra-prostatic UroLift(®) implant procedure seemed feasible, efficacious for LUTS and well tolerated, especially concerning sexual outcomes. Further study of the UroLift(®) implant in France is currently being planned.
评估前列腺内UroLift®植入术在4例有症状的良性前列腺增生患者中的可行性、耐受性和短期疗效。
4例有症状的良性前列腺增生患者，已接受α受体阻滞剂治疗，在全身麻醉下连续接受前列腺内UroLift®植入术。术后放置膀胱导管。术后7天停用α受体阻滞剂治疗。记录患者的临床和形态学特征。术前及术后1个月评估下尿路症状（国际前列腺症状评分，IPSS）、性症状（国际勃起功能指数5项问卷，IIEF5；男性性功能和射精功能问卷，MSHQ-EjD）、最大尿流率和排尿后残余尿量。
中位年龄为69岁[52 - 74岁]，中位前列腺体积为50 cm³[40 - 80 cm³]。中位手术时间为11分钟[6 - 15分钟]。术中及术后过程顺利。术后1个月，平均国际前列腺症状评分改善46%，国际前列腺症状评分生活质量部分改善58%。1例患者报告其尿路和性症状无改善。在其他3例患者中，最大尿流率有所改善，2例患者排尿后残余尿量改善，1例患者情况类似。未报告勃起或射精功能有改变。
根据我们的初步经验，前列腺内UroLift®植入术似乎可行，对下尿路症状有效且耐受性良好，尤其是在性方面的结果。目前正在计划在法国对UroLift®植入术进行进一步研究。
